Working… Menu

Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04357730
Recruitment Status : Active, not recruiting
First Posted : April 22, 2020
Last Update Posted : May 10, 2021
Genentech, Inc.
University of Colorado, Denver
National Jewish Health
Beth Israel Deaconess Medical Center
Long Island Jewish Medical Center
Scripps Health
St. Mary's Medical Center
University of Miami
Ben Taub Hospital
Methodist Dallas Medical Center
Information provided by (Responsible Party):
Ernest E. Moore, MD, Denver Health and Hospital Authority

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : March 21, 2021
Estimated Study Completion Date : November 2021
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 November 7, 2021
November 15, 2021